220303US0X PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Denis-Claude ROY,

SERIAL NO:

10/088,072

FILED: FOR: March 20, 2002

RHODAMINE DERIVATIVES FOR PI

GAU:

1651

EXAMINER: AFREMOVA, V.

ODYNAMI DIAGNOSIS AND TREATMENT

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,

MAIRR & NEUSTADT P.C.

Norman F. Oblon

Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03)

Daniel R. Evans, Ph.D. Registration No.55,868

Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO.		SERIAL NO. 10/088,072					
			220303US0X PCT							
				APPLICANT						
LIST OF RE	EFEF	RENCES CITED BY AP	STICYUS .	Denis-Claude ROY, et al.						
		1	den .	FILING DATE March 20, 2002		GROUP				
O IM 2 6 MIN 3				March 20, 2002	1651					
		/ 2	W.	S. PATENT DOCUMENTS						
EXAMINER INITIAL		DOCUMENT NUMBER	MIRATATA	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE			
,	AA	5,556,992	09/17/96	GABOURY ET AL						
/	AB	5,773,460	06/30/98	GABOURY ET AL						
1	AC	4,612,007	09/16/86	EDELSON						
1	AD	5,798,523	08/25/98	VILLENEUVE ET AL						
/	AE									
,	AF									
1	AG			,						
1	АН									
	AI					*****				
,	AJ									
,	AK									
,	AL									
<i>F</i>	АМ									
,	AN									
	,		FO	REIGN PATENT DOCUMENTS						
		DOCUMENT DATE		COUNTRY		TRANSLATION YES NO				
F	AO	•								
,	AP									
<i>A</i>	AQ									
A	AR	•								
1	AS	-								
/	AT									
ļ ,	AU									
	ΑV	·								
		OTHER RE	FERENCES (Including Author, Title, Date, Pertinen	t Pages, e	tc.)				
A	ΑW	Cavazzana-Calvo M., et al. (1990) Transplantation, 50:1-7.								
,	AX	Tittle, T.V. et al. (1997) Blood 89-4652-58								
,	AY	Harris, D.T. et al. (1999) Bone Marrow Transplantation, 23:137-44								
,	AZ	Daniell, M.D., Hill, J.S. (1991) Aust. N.Z. Surg., 61:340-348 Additional References sheet(s) attached								
Examiner					Date Considered					
				t citation is in conformance with MPEP 6 with next communication to applicant.	1 09; Draw lii	ne through	citation it	not in		

ATTY DOCKET NO. SERIAL NO. Form PTO 1449 (Modified) RTMENT OF COMMERCE 220303US0X PCT 10/088,072 **APPLICANT** LIST OF REFERENCES CITED BY APPLICANT Denis-Claude ROY, et al. **GROUP FILING DATE** 1651 March 20, 2002 OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.) Raab, O. (1990) Infusoria Z., Biol., 39:524-546 BA Tappeiner, V.H., Jesionek A. (1903) Muench Med Wochneshr, 47:2042-2044 BB Hausman W. (1911) Biochem Z., 30:276-316 BC Dougherty, T.J. (1974) J. Natl. Cancer Inst., 51:1333-1336 BD Dougherty, T.J. et al. (1975) J. Natl. Cancer Inst., 55:115-121. ΒE Dougherty, T.J. et al. (1978) Cancer Reserch, 38:2628-2635. BF Dougherty, T.J. (1984) Urol. Suppl., 23:61-64 BG Dougherty, T.J. (1987) Photochem. Photobiol., 45:879-889 вн Greinix, H.T., et al. Blood (1998) 92:3098-3104. ВΙ Hunt, D.W., et al. (1999) Immunopharmacology, 41:31-44. BJ Hryhorenko E.A., et al. (1998) Immunopharmacology, 40:231-40. BK King, D.E., et al. (1999) Scand. J. Immunol. 49:184-92. BL Zic, J.A., et al., Therapeutic Apheresis (1999) 3:50-62. ВМ Darzynkiewick, Z., Carter S. (1988) Cancer Researach, 48:1295-1299. BN. Oseroff, A.R. (1992) In Photodynamic therapy (Henderson, B.W., Dougherty, T.J., eds.) New York: Marcel Dekker, pp. 79-91. BO Bernal, S.D., et al., (1983 Science, 222: 169-172. BP Powers, S.K., et al. (1987) J. Neurosurg., 67:889-894 BQ **Date Considered** Examiner *Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

10		P. Cm. S							
	JAH 2	Į į	DEPARTMENT OF COMMERCE	ATTY DOCKET NO.	SERIAL NO.				
(Modified) TENT AND TRADEMARK OFFICE				220303US0X PCT	10/088,072				
	DECE	2511250.0	ITED DV ADDI IOANT	APPLICANT					
LIST OF	KEFE	RENCES C	ITED BY APPLICANT		ide ROY, et al.				
				FILING DATE	GROUP				
				March 20, 2002	1651				
			OTHER REFERENCES (Including Author, Title, Date, Pertinent	Pages, etc.)				
	BR	Pilarski, L	.M. (1995) American Journ	al of Hematology, 49:323-335					
-	BS	Morliere,	P., et al. (1990) Photochem	istry and Photobiology, 52(4):703-710.					
	ВТ	Chi-Wei L	in (1990) In Photodynamic	therapy of neoplastic disease, Vol. II, CRO	C Press, pp. 79-101.				
	ви	Albert, M.	L., et al. Nature (1998) 392	-86-89					
	BV	Lozzio, B	B. and Lozzio, C.B. (1979)	Cancer Research, 3(6):363-370.					
	вw	Roy, D.C.	, et al., JNCI (1996), 88:11:	36-1145.					
	вх	Taswell C	., The Journal of Immunolo	gy (1981) 126:1614-1619.					
	BY	Graft-vs-Host Disease, Ferrara, J.L.M., Deeg, H.J., Burakoff, S.J., eds., Marcel Dekker, New York (1997).							
	BZ	Bone Marrrow Transplantation, Forman, S.J., Blume K.G., Thomas, E.D., eds., Blackwell Scientific Publications, Cambridge, MA, USA, (1994).							
	CA	Sullivan, I	K.M., et al., Am. Soc. Hema	atol., Educ. Program Book, (1998), 198-21	4.				
				f Some Bromine-Substituted Rhodamine [DTOCHEM. PHOTOBIOL. (1996), 63(2), 1	Oyes: Synthesis, Photophysical Properties and 61-8, XP-000979188.				
	СС	Villeneuve, Luc: "Ex vivo photodynamic purging in chronic myelogenous leukemia and other neoplasias with rhodamine derivatives:, Biotechnol. Appl. Biochem. (1999), 30(1), 1-17, XP000979118, page 1.							
	CD	Faseb Jo	urnal, (April 20, 2000), Vol.	14, No. 6, pp A-1074 – Abstract					
	CE	Christof, l	, et al (1998) British Journ	al of Haematology, 101:722-727					
	CF [']								
	CG								
-	СН								
Examiner					Date Considered				
*Examiner: In	nitial if r	eference is	considered, whether or no	t citation is in conformance with MPEP 60:	9; Draw line through citation if not in				